GrantR21CA
DNA methylation, Liquid Biopsy, and Pancreatic Cancer
- Activity
- R21
- Institute
- CA
- Fiscal years
- 2022–2023
- Amount counted
- $391,100
These are registry fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Abstract public domain (NIH RePORTER)
PROJECT SUMMARY/ABSTRACT Pancreatic ductal adenocarcinoma (PDAC), has an overall survival rate of 9%, and detection of PDAC is a high priority area for the NCI. Only 10-20% of patients with PDAC have a primarily resectable disease, while 50- 60% of patients are diagnosed with irresectable disease. Neoadjuvant chemotherapy maybe beneficial to these patients. Disease monitoring of PDAC patients in the neoadjuvant setting is by Computed tomography (CT) or detection of CA19-9 levels. These approaches can be imprecise and not predictive of tumor burden. Thus, there is a need to develop sensitive and specific biomarkers to assess disease burden and monitor patients with PDAC undergoing neoadjuvant therapy. Recently we showed that aberrant DNA methylation analysis in cell-free DNA may be an attractive liquid biopsy approach for the detection of PDAC. The objective of this proposal is to validate our liquid biopsy approach and demonstrate its utility. In Aim 1, we will validate our Methyl 10 biomarkers for the detection of early-stage PDAC. In Aim, 2, we investigate whether our Methyl 10 biomarkers can detect minimal residual disease in pancreatic cancer patients. At the completion of these studies, we will have validated and developed a novel DNA methylation biomarker set that is highly robust in the detection of PDAC and highlight its clinical significance for monitoring treatment strategies in PDAC patients.
Public health relevance public domain (NIH RePORTER)
PROJECT NARRATIVE Early detection of pancreatic cancer is one of the leading priorities of the NCI. We have developed liquid biopsy for the measurement of pancreatic cancer. This feasibility study will enable the development of a non- invasive approach for early cancer and monitor for minimal residual disease in pancreatic cancer patients.